 |
|
 |
Prescription Drugs |
|
|
Antihormonal Therapies
Aromatase Inhibitors Reinvigorate a Mature Market
Publication Date July 2005
Publisher Datamonitor
Product Type Strategic Report
Pages 122
ISBN Number not applicable
Product Code DAT358
|
|
|
Summary
The antihormonal cancer therapy market is characterized by a mature nature and a relatively high level of saturation. Despite this, growth will continue slowly at a CAGR of 0.9% during 2004-14, with those areas in decline offset by clear potential from new products and line extensions. Generic competition continues to threaten, although effective lifecycle management can dilute the overall impact.
Highlights
- The antihormonal therapies market was worth $4.8 billion in 2004, and is set to grow at a CAGR of 0.9% to reach $5.5 billion by 2014. This is due to the maturity of the market and its relative saturation, as well as the increasing threat of key patent expiries and entry of generic competition.
- Despite the decline of some therapy classes, opportunities for new growth do exist. The aromatase inhibitors will drive significant market expansion, particularly in light of recent positive clinical trial data and ASCO recommendations that will serve to increase their profile and significantly increase uptake.
- The remaining drug classes within the antihormonal therapies market will see a decline in sales growth, although volume is expected to remain more or less stable. Despite generic competition, the maturity and saturated nature of this market means further pipeline breakthroughs are unlikely unless significant clinical superiority is demonstrated.
Scope
- Overview of the current antihormonal therapies market, including profiles of key products and events impacting each during 2004-14
- Assessment of current and future opportunities and threats in the antihormonal therapies market across the seven major pharmaceutical markets
- Individual country, EU5 and global sales from 2004 to 2014 for branded products and generics
- Detailed discussion of assumptions and events used in our forecast analysis, plus commercial impact and lifecycle management case studies
Reasons to Purchase
- Understand market specific drivers and predict the future potential of key antihormonal therapies
- Quantify the impact of key patent expiries, product launches and clinical trial results
- Adopt knowledge to drive strategic planning for mature products and optimize the market penetration of new entrants
|
Content
- Chapter 1 Executive Summary
- Datamonitor insight into the antihormonal therapies market
- Chapter 2 Market Definition And Overview
- Market definition for this report
- L2A - Cytostatic hormones
- L2A3 - Luteinizing hormone-releasing hormone (LHRH) analogs
- L2B - Cytostatic hormone antagonists
- L2B1 - Anti-estrogens
- L2B2 - Anti-androgens
- L2B3 - Aromatase inhibitors
- L2B9 - Other hormone antagonists
- Excluded drug classes
- L2A1 - Cytostatic estrogens
- L2A2 - Cytostatic progestogens
- L2A9 - Other cytostatic hormones
- Current market situation
- Chapter 3 Country Market Assessments
- Current and future opportunities and threats in the antihormonal therapies market
- Global opportunities and threats
- Opportunities
- Threats
- US: opportunities and threats
- Opportunities
- Threats
- Japan: opportunities and threats
- Opportunities
- Threats
- EU5: opportunities and threats
- Opportunities
- Threats
- France: opportunities and threats
- Opportunities
- Threats
- Germany: opportunities and threats
- Opportunities
- Threats
- Italy: opportunities and threats
- Opportunities
- Threats
- Spain: opportunities and threats
- Opportunities
- Threats
- UK: opportunities and threats
- Opportunities
- Threats
- Summary of environmental issues affecting the antihormonal therapies market size
- Chapter 4 Forecast Analysis
- Overriding assumptions and effects
- Effect of Medicare Modernization Act
- Biennial price cut in Japan
- LHRH analogs
- Lupron (leuprolide)
- Despite increasing competition from super generics, Lupron remains the LHRH analog leader
- Eligard (leuprolide)
- Eligard's super-generic status is expected to erode Lupron's sales
- Viadur (leuprolide)
- Yearly formulation for advanced disease is likely to limit Viadur's use
- Zoladex (goserelin)
- Despite clinical efficacy to Lupron, Zoladex's difficult and painful administration may deter patients
- Decapeptyl (triptorelin)
- Genericized status has eroded Decapeptyl's sales, as well as physician favor for Lupron
- Plenaxis (abarelix)
- Despite withdrawal from US market due to slow uptake, Plenaxis may realize success in Europe
- Suprefact (buserelin)
- Inconvenience of administration severely limits use of Suprefact
- Anti-estrogens
- Nolvadex (tamoxifen)
- Although Nolvadex is set to lose its gold-standard status to an aromatase inhibitor, its presence will always be felt in the breast cancer market
- Fareston (toremifene)
- Fareston has always been in tamoxifen's shadow, although an approval for atamestane may increase its sales
- Anti-androgens
- Casodex (bicalutamide)
- Despite a heavily genericized market, the branded Casodex remains the clear leader
- Eulexin (flutamide)
- Inconvenience of dosing schedule compared to other anti-androgens has caused its use to decline
- Anandron (nilutamide)
- Compared to Casodex, Anandron has a less favorable toxicity profile, meaning that physicians favor the former drug
- Androcur (cyproterone)
- Androcur's association with potentially severe hepatotoxicity has severely restricted its use
- Aromatase inhibitors
- Arimidex (anastrozole)
- Arimidex's status as the leading aromatase inhibitor has been set in stone by recent ATAC results and ASCO recommendations
- Femara (letrozole)
- Recent ASCO recommendations and potential additional indications will serve to boost Femara's sales
- Aromasin (exemestane)
- Difference in mechanism of action may provide Aromasin with new opportunities
- Cytadren (aminoglutethimide)
- Age of product and advent of more effective products has left Cytadren redundant
- Other hormone antagonists
- Faslodex (fulvestrant)
- Additional indications and complexity of formulation will ensure that Faslodex's sales continue to rise
- Pipeline products
- Vantas (histrelin)
- Yearly formulation is likely to limit Vantas's potential, particularly in the saturated LHRH analog market
- Atamestane (atamestane)
- Atamestane's development in combination with Orion Corp's Fareston may distinguish it from the other aromatase inhibitors
- Evista (raloxifene)
- Forecasts
- Chapter 5 Commercial Impact And Lifecycle Management: Case Studies
- Introduction
- Case study
- The rising profile of the aromatase inhibitors
- Link between aromatase inhibitors and anti-estrogens
- Demise of tamoxifen
- Arrival of the aromatase inhibitors
- Clinical superiority in treatment of breast cancer?
- ASCO recommendations
- Clinical superiority in prevention?
- Opportunities for further growth
- Case study
- Failure of Plenaxis to enter a mature market
- Saturation of the LHRH analogs market
- Initial high expectations
- Multiple drawbacks
- Different strategy may result in European success
- Physician prescribing patterns difficult to shift
- Potentially shifting paradigms in treatment of prostate cancer
- Superiority in all aspects
- Case study
- AstraZeneca's optimal strategy
- First-to-market status
- Effective lifecycle management diluted generic erosion of Nolvadex
- Arimidex as replacement for Nolvadex?
- Maintenance of lead position
- Future challenges to overcome
- Appendix A - Market Data And Major Brand Key Facts
- L2A3 (LHRH analogs) class market data
- L2B1 (anti-estrogens) class market data
- L2B2 (anti-androgens) class market data
- L2B3 (aromatase inhibitors) class market data
- L2B9 (other hormone antagonists) class market data
- Sales data and forecasts
- PowerPoint Executive Presentation
- Appendix B - Sales Forecasts
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- EU5 forecasts
- Global forecasts
- Appendix C
- Bibliography
- Report methodology
- List of Tables
- Table 1: Key players in the antihormonal therapies market
- Table 2: Antihormonal therapy sales in the seven major markets by drug class, 2003-04
- Table 3: Lupron: key facts
- Table 4: Eligard: key facts
- Table 5: Viadur: key facts
- Table 6: Zoladex: key facts
- Table 7: Decapeptyl: key facts
- Table 8: Plenaxis: key facts
- Table 9: Suprefact: key facts
- Table 10: Nolvadex: key facts
- Table 11: Fareston: key facts
- Table 12: Casodex: key facts
- Table 13: Eulexin: key facts
- Table 14: Anandron: key facts
- Table 15: Androcur: key facts
- Table 16: Arimidex: key facts
- Table 17: Femara: key facts
- Table 18: Aromasin: key facts
- Table 19: Lentaron: key facts
- Table 20: Cytadren: key facts
- Table 21: Faslodex: key facts
- Table 22: Forecasts for LHRH analogs in the US to 2014
- Table 23: Forecasts for aromatase inhibitors in the US to 2014
- Table 24: Forecasts for anti-androgens, anti-estrogens and other hormone antagonists in the US to 2014
- Table 25: Forecasts for LHRH analogs in Japan to 2014
- Table 26: Forecasts for aromatase inhibitors and anti-androgens in Japan to 2014
- Table 27: Forecasts for anti-estrogens and other hormone antagonists in Japan to 2014
- Table 28: Forecasts for LHRH analogs in France to 2014
- Table 29: Forecasts for aromatase inhibitors in France to 2014
- Table 30: Forecasts for anti-androgens in France to 2014
- Table 31: Forecasts for anti-estrogens and other hormone antagonists in France to 2014
- Table 32: Forecasts for LHRH analogs in Germany to 2014
- Table 33: Forecasts for aromatase inhibitors in Germany to 2014
- Table 34: Forecasts for anti-androgens in Germany to 2014
- Table 35: Forecasts for anti-estrogens and other hormone antagonists in Germany to 2014
- Table 36: Forecasts for LHRH analogs in Italy to 2014
- Table 37: Forecasts for aromatase inhibitors in Italy to 2014
- Table 38: Forecasts for anti-androgens, anti-estrogens and other hormone antagonists in Italy to 2014
- Table 39: Forecasts for LHRH analogs in Spain to 2014
- Table 40: Forecasts for aromatase inhibitors in Spain to 2014
- Table 41: Forecasts for anti-androgens, anti-estrogens and other hormone antagonists in Spain to 2014
- Table 42: Forecasts for LHRH analogs in the UK to 2014
- Table 43: Forecasts for aromatase inhibitors in the UK to 2014
- Table 44: Forecasts for anti-androgens in the UK to 2014
- Table 45: Forecasts for anti-estrogens and other hormone antagonists in the UK to 2014
- Table 46: EU5 forecasts for LHRH analogs to 2014
- Table 47: EU5 forecasts for aromatase inhibitors to 2014
- Table 48: EU5 forecasts for anti-androgens to 2014
- Table 49: EU5 forecasts for anti-estrogens and other hormone antagonists to 2014
- Table 50: Global forecasts for LHRH analogs to 2014
- Table 51: Global forecasts for aromatase inhibitors to 2014
- Table 52: Global forecasts for anti-androgens to 2014
- Table 53: Global forecasts for anti-estrogens and other hormone antagonists to 2014
- List of Figures
- Figure 1: Seven market population aged 60 and over, 1950-2050
- Figure 2: Increasing incidence of breast and prostate cancer with increasing age
- Figure 3: Global oncology sales, 2003-09
- Figure 4: Summary of regional opportunities and threats affecting the antihormonal therapies market
|
|
|
